Literature DB >> 24992401

The use of infliximab in X-linked agammaglobulinaemia associated enteropathy.

P T Davey1, C J Tan, K Gardiner.   

Abstract

Granulomatous small bowel enteropathy is an unusual presentation associated with X-linked agammaglobulinaemia. We present a rare case of this condition that was further complicated by an enterocutaneous fistula and report our experience managing this condition successfully with infliximab, which has not been documented in the literature previously.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24992401      PMCID: PMC4473971          DOI: 10.1308/003588414X13814021679078

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  5 in total

1.  X-linked agammaglobulinemia: report on a United States registry of 201 patients.

Authors:  Jerry A Winkelstein; Mary C Marino; Howard M Lederman; Stacie M Jones; Kathleen Sullivan; A Wesley Burks; Mary Ellen Conley; Charlotte Cunningham-Rundles; Hans D Ochs
Journal:  Medicine (Baltimore)       Date:  2006-07       Impact factor: 1.889

Review 2.  Crohn's disease: an immunodeficiency?

Authors:  Christian Folwaczny; Jürgen Glas; Helga-Paula Török
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-06       Impact factor: 2.566

3.  Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID).

Authors:  I Chua; R Standish; S Lear; M Harbord; E Eren; M Raeiszadeh; S Workman; D Webster
Journal:  Clin Exp Immunol       Date:  2007-09-05       Impact factor: 4.330

4.  Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia.

Authors:  K Washington; T T Stenzel; R H Buckley; M R Gottfried
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

5.  Granulomatous disease in common variable immunodeficiency.

Authors:  Omür Ardeniz; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2009-08-28       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.